JP2015525794A - 乳児においてｒｓｖ及び百日咳菌に対する免疫応答を惹起するための方法 - Google Patents

乳児においてｒｓｖ及び百日咳菌に対する免疫応答を惹起するための方法 Download PDF

Info

Publication number
JP2015525794A
JP2015525794A JP2015525952A JP2015525952A JP2015525794A JP 2015525794 A JP2015525794 A JP 2015525794A JP 2015525952 A JP2015525952 A JP 2015525952A JP 2015525952 A JP2015525952 A JP 2015525952A JP 2015525794 A JP2015525794 A JP 2015525794A
Authority
JP
Japan
Prior art keywords
rsv
vaccination regimen
protein
kit
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2015525952A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015525794A5 (https=
Inventor
ステフ，アン−ミュリエル
トゥーサン，ジャン−フランソワ
テマーマン，ステファン，ティー．
Original Assignee
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グラクソスミスクライン バイオロジカルズ ソシエテ アノニム, グラクソスミスクライン バイオロジカルズ ソシエテ アノニム filed Critical グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Publication of JP2015525794A publication Critical patent/JP2015525794A/ja
Publication of JP2015525794A5 publication Critical patent/JP2015525794A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2015525952A 2012-08-06 2013-08-05 乳児においてｒｓｖ及び百日咳菌に対する免疫応答を惹起するための方法 Withdrawn JP2015525794A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261679928P 2012-08-06 2012-08-06
US61/679,928 2012-08-06
US201313138358A 2013-03-15 2013-03-15
US13/,835,829 2013-03-15
PCT/IB2013/001722 WO2014024026A1 (en) 2012-08-06 2013-08-05 Method for eliciting in infants an immune response against rsv and b. pertussis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018127389A Division JP2018172417A (ja) 2012-08-06 2018-07-04 乳児においてｒｓｖ及び百日咳菌に対する免疫応答を惹起するための方法

Publications (2)

Publication Number Publication Date
JP2015525794A true JP2015525794A (ja) 2015-09-07
JP2015525794A5 JP2015525794A5 (https=) 2016-09-15

Family

ID=50067471

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015525952A Withdrawn JP2015525794A (ja) 2012-08-06 2013-08-05 乳児においてｒｓｖ及び百日咳菌に対する免疫応答を惹起するための方法

Country Status (5)

Country Link
JP (1) JP2015525794A (https=)
AU (1) AU2013301312A1 (https=)
CA (1) CA2879939A1 (https=)
SG (1) SG11201500573RA (https=)
WO (1) WO2014024026A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016527294A (ja) * 2013-08-05 2016-09-08 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 併用免疫原性組成物
JP2022521760A (ja) * 2019-02-28 2022-04-12 ノババックス，インコーポレイテッド Ｒｓｖ感染によって引き起こされる疾患又は障害を予防する方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2970398B1 (en) 2013-03-13 2024-05-08 The United States of America, as Represented by The Secretary, Department of Health and Human Services Prefusion rsv f proteins and their use
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
SG11202003333WA (en) * 2017-10-18 2020-05-28 Pasteur Institut Bordetella strains expressing serotype 3 fimbriae
EP3890770A4 (en) * 2018-12-05 2022-09-28 Sanofi Pasteur, Inc. PERTUSSIS BOOST VACCINE

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010522540A (ja) * 2007-03-21 2010-07-08 アイディー バイオメディカル コーポレイション オブ ケベック キメラ抗原
WO2010149745A1 (en) * 2009-06-24 2010-12-29 Glaxosmithkline Biologicals S.A. Recombinant rsv antigens
WO2011008974A2 (en) * 2009-07-15 2011-01-20 Novartis Ag Rsv f protein compositions and methods for making same
WO2012103361A1 (en) * 2011-01-26 2012-08-02 Novartis Ag Rsv immunization regimen

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4707543A (en) 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
CA1283827C (en) 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
ES2044959T3 (es) 1986-12-23 1994-01-16 Univ Leland Stanford Junior Exotoxina de tos ferina modificada.
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US5726292A (en) 1987-06-23 1998-03-10 Lowell; George H. Immuno-potentiating systems for preparation of immunogenic materials
KR0168039B1 (ko) 1987-09-04 1999-01-15 로버트 디. 웨스트 재조합 dna에서 유도한 보르데텔라 외독소 소단위체의 유사체 및 그를 포함하는 백신
IT1223334B (it) 1987-11-02 1990-09-19 Sclavo Spa Polipeptidi immunologicamente attivi con una tossicita' alterata utili per la preparazione di un vaccino antipertosse
GB8727489D0 (en) 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
ATE127347T1 (de) 1989-04-28 1995-09-15 Sclavo Spa Pertussistoxin-mutanten, dieselbe produzierende bordetella-stämme und ihre verwendung als vakzin gegen pertussis.
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
ES2080941T3 (es) 1990-02-12 1996-02-16 Smithkline Beecham Biolog Nueva vacuna y procedimiento para la misma.
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
SG48365A1 (en) 1992-05-23 1998-04-17 Smithkline Beecham Biolog Combined vaccines comprising hepatitis b surface antigen and other antigens
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
US5776468A (en) 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
PL181241B1 (pl) 1993-11-17 2001-06-29 Deutsche Om Arzneimittel Gmbh Disacharydy beta(1 6)glukozoaminowe, sposób wytwarzania disacharydu beta(1 6) glukozoaminowego, zawierająca je kompozycja farmaceutyczna i środek immunomodulujący i/lub przeciwnowotworowy oraz szczepionka
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
PL184872B1 (pl) 1995-06-23 2003-01-31 Smithkline Beecham Biolog Kombinowana szczepionkaĆ zestaw do przygotowania kombinowanej szczepionkiĆ sposób wytwarzania kombinowanej szczepionki i jej zastosowanie
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
GB9623233D0 (en) 1996-11-07 1997-01-08 Smithkline Beecham Biolog Vaccine composition
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
AU7924598A (en) 1998-06-08 1999-12-30 Sca Emballage France Fast flattening packaging
CN1168702C (zh) 1998-06-30 2004-09-29 Om药业 酰基-二肽类化合物,其制备方法以及含有前述化合物的药物组合物
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US6256533B1 (en) 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
US6379324B1 (en) 1999-06-09 2002-04-30 The Procter & Gamble Company Intracutaneous microneedle array apparatus
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
WO2001046127A1 (fr) 1999-12-22 2001-06-28 Om Pharma Pseudodipeptides acyles porteurs d'un bras auxiliaire fonctionnalise
CZ20024224A3 (cs) 2000-06-29 2003-05-14 Glaxosmithkline Biologicals S. A. Farmaceutický prostředek
US7524509B2 (en) 2001-03-09 2009-04-28 Id Biomedical Corporation Of Quebec Proteosome-liposaccharide vaccine adjuvant
US7157465B2 (en) 2001-04-17 2007-01-02 Dainippon Simitomo Pharma Co., Ltd. Adenine derivatives
US20040087992A1 (en) 2002-08-09 2004-05-06 Vladimir Gartstein Microstructures for delivering a composition cutaneously to skin using rotatable structures
EP1455700A4 (en) 2001-11-16 2007-02-14 3M Innovative Properties Co METHODS AND COMPOSITIONS RELATED TO MRI COMPOUNDS AND TO TOLL-TYPE RECEPTOR (TLR) PATHWAYS
JP2006517974A (ja) 2003-02-13 2006-08-03 スリーエム イノベイティブ プロパティズ カンパニー Ｉｒｍ化合物およびトル様受容体８に関する方法および組成物
US7368537B2 (en) 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection
EP1667712B1 (en) 2003-10-02 2010-07-21 GlaxoSmithKline Biologicals S.A. B. pertussis antigens and use thereof in vaccination
BRPI0402630B8 (pt) 2004-07-05 2021-05-25 Fund Butantan processo de obtenção de vacina pertussis celular menos reatogênica
WO2006055844A2 (en) 2004-11-18 2006-05-26 3M Innovative Properties Company Method of contact coating a microneedle array
WO2006055799A1 (en) 2004-11-18 2006-05-26 3M Innovative Properties Company Masking method for coating a microneedle array
BRPI0519923A8 (pt) 2004-12-17 2018-01-23 De Staat Der Nederlanden Vertegenwoordigd Door De Mini Van Vws polipeptídeo, seqüência de dna, vetor de dna, anticorpo, bactéria, método para produzir lps parcialmente 3-0-desacilado, composição, usos da bactéria, e de lps de bordetella isolado compreendendo lps pelo menos parcialmente 3-0-desacilado, vacina, e, método in vitro para a desacilação de lps gram-negativo ou de composições compreendendo lps gram-negativo, e, para induzir uma resposta imune contra bordetella.
ES2817249T3 (es) 2007-04-16 2021-04-06 Corium Inc Matrices de microagujas obtenidas mediante disolución y colada que contienen un principio activo
WO2009048607A1 (en) 2007-10-10 2009-04-16 Corium International, Inc. Vaccine delivery via microneedle arrays
EP2429627B1 (en) 2009-04-24 2017-06-14 Corium International, Inc. Methods for manufacturing microprojection arrays
EP2445527A2 (en) 2009-06-24 2012-05-02 ID Biomedical Corporation of Quebec Vaccine
WO2012089231A1 (en) 2010-12-30 2012-07-05 Okairòs Ag Paramyxovirus vaccines

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010522540A (ja) * 2007-03-21 2010-07-08 アイディー バイオメディカル コーポレイション オブ ケベック キメラ抗原
WO2010149745A1 (en) * 2009-06-24 2010-12-29 Glaxosmithkline Biologicals S.A. Recombinant rsv antigens
WO2011008974A2 (en) * 2009-07-15 2011-01-20 Novartis Ag Rsv f protein compositions and methods for making same
WO2012103361A1 (en) * 2011-01-26 2012-08-02 Novartis Ag Rsv immunization regimen

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ＣＬＩＮＩＣＡＬ ＯＢＳＴＥＴＲＩＣＳ ＡＮＤ ＧＹＮＥＣＯＬＯＧＹ, vol. 55, no. 2, JPN6017013032, June 2012 (2012-06-01), pages 474 - 486, ISSN: 0003538587 *
ＪＯＵＲＮＡＬ ＯＦ ＩＮＦＥＣＴＩＯＵＳ ＤＩＳＥＡＳＥＳ, vol. 180, no. 3, JPN6017013034, 1999, pages 714 - 719, ISSN: 0003538588 *
ＶＡＣＣＩＮＥ, vol. 21, no. 24, JPN6017013037, 2003, pages 3465 - 3467, ISSN: 0003538589 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016527294A (ja) * 2013-08-05 2016-09-08 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 併用免疫原性組成物
JP2022521760A (ja) * 2019-02-28 2022-04-12 ノババックス，インコーポレイテッド Ｒｓｖ感染によって引き起こされる疾患又は障害を予防する方法

Also Published As

Publication number Publication date
SG11201500573RA (en) 2015-02-27
WO2014024026A8 (en) 2015-04-02
CA2879939A1 (en) 2014-02-13
AU2013301312A1 (en) 2015-03-19
WO2014024026A1 (en) 2014-02-13

Similar Documents

Publication Publication Date Title
US20230390381A1 (en) Immunogenic combinations
CN104755100B (zh) 用于在婴儿中引发针对rsv和百日咳博德特氏菌的免疫应答的方法
JP6564367B2 (ja) 併用免疫原性組成物
JP5711972B2 (ja) 組換えｒｓｖ抗原
JP5796011B2 (ja) ワクチン
JP6062245B2 (ja) 組換えｒｓｖ抗原
JP2011528222A (ja) キメラ呼吸器合胞体ウイルスポリペプチド抗原
ES2304960T3 (es) Vacuna combinada contra streptococcus pneumoniae y virus sincicial respiratorio (rsv).
JP2010522540A (ja) キメラ抗原
JP2015525794A (ja) 乳児においてｒｓｖ及び百日咳菌に対する免疫応答を惹起するための方法
ES2924914T3 (es) Vacuna contra rinovirus humano
HK40060960A (en) Immunogenic combinations

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160728

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160728

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170418

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171018

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180306

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20180706